Evidence map›Paper›PMID 28496911›Full record

ArticleJournal of atrial fibrillation2013

Anticoagulation and Clinical Outcomes in Heart Failure Patients With Atrial Fibrillation: Findings From the ADHERE Registry.

Zubin J Eapen, Xiaojuan Mi, Gregg C Fonarow, Soko Setoguchi, Jonathan P Piccini, Roger M Mills, Winslow Klaskala, Lesley H Curtis, Adrian F Hernandez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of atrial fibrillation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Zubin J EapenDuke Clinical Research Institute.
Xiaojuan MiDuke Clinical Research Institute.
Gregg C FonarowAhmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles.
Soko SetoguchiDuke Clinical Research Institute.
Jonathan P PicciniDuke Clinical Research Institute.
Roger M MillsJanssen Research and Development, LLC, Raritan, New Jersey.
Winslow KlaskalaJohnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, New Jersey.
Lesley H CurtisDuke Clinical Research Institute.
Adrian F HernandezDuke Clinical Research Institute.
Clinical Research Institute · USDuke University · USJanssen (United States) · USJohnson & Johnson (United States) · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The risks and benefits of anticoagulation for patients with both heart failure and atrial fibrillation are unclear. We hypothesized that anticoagulation was associated with improved clinical outcomes of heart failure patients with atrial fibrillation independent of other risk factors. We conducted a retrospective cohort study of clinical registry data linked to Medicare claims for new users of oral anticoagulation (warfarin) without contraindications, discharged home alive, and stratified by CHADS

Indexed as

Atrial FibrillationHeart FailureHemorrhageMortalityThromboembolismWarfarin

Identifiers

PMID28496911
PMCPMC5153135
OpenAlexW3023151404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.